Literature DB >> 19671042

The VHL tumor suppressor: master regulator of HIF.

Volker H Haase1.   

Abstract

Hypoxia-Inducible Factors (HIFs) are heterodimeric oxygen-sensitive basic helix-loop-helix transcription factors that play central roles in cellular adaptation to low oxygen environments. The von-Hippel Lindau tumor suppressor (pVHL) is the substrate recognition component of an E3 ubiquitin ligase and functions as a master regulator of HIF activity by targeting the hydroxylated HIF-alpha subunit for ubiquitylation and rapid proteasomal degradation under normoxic conditions. Mutations in pVHL can be found in familial and sporadic hemangioblastomas, clear cell carcinomas of the kidney, pheochromocytomas and inherited forms of erythrocytosis, illustrating the importance of disrupted molecular oxygen sensing in the pathogenesis of these diseases. Tissue-specific gene targeting of pVHL in mice has demonstrated that efficient execution of HIF proteolysis is critically important for normal tissue physiology, and has provided novel insights into the functional consequences of HIF activation on the cellular and tissue level. Here we focus on the contribution of individual HIF transcription factors to the development of VHL phenotypes and discuss how the pVHL/HIF axis could be exploited pharmacologically.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19671042      PMCID: PMC3622710          DOI: 10.2174/138161209789649394

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  119 in total

Review 1.  Renal cysts, renal cancer and von Hippel-Lindau disease.

Authors:  H P Neumann; B Zbar
Journal:  Kidney Int       Date:  1997-01       Impact factor: 10.612

2.  von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease.

Authors:  A O Vortmeyer; J R Gnarra; M R Emmert-Buck; D Katz; W M Linehan; E H Oldfield; Z Zhuang
Journal:  Hum Pathol       Date:  1997-05       Impact factor: 3.466

3.  The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins.

Authors:  A Pause; S Lee; R A Worrell; D Y Chen; W H Burgess; W M Linehan; R D Klausner
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

4.  HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron.

Authors:  Stefano J Mandriota; Kevin J Turner; David R Davies; Paul G Murray; Neil V Morgan; Heidi M Sowter; Charles C Wykoff; Eamonn R Maher; Adrian L Harris; Peter J Ratcliffe; Patrick H Maxwell
Journal:  Cancer Cell       Date:  2002-06       Impact factor: 31.743

5.  Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.

Authors:  Malgorzata Zatyka; Nancy Fernandes da Silva; Steven C Clifford; Mark R Morris; Michael S Wiesener; Kai-Uwe Eckardt; Richard S Houlston; Frances M Richards; Farida Latif; Eamonn R Maher
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

6.  Hepatic hemangioblastoma. An unusual presentation in a patient with von Hippel-Lindau disease.

Authors:  A M Rojiani; D A Owen; K Berry; B Woodhurst; F H Anderson; C H Scudamore; S Erb
Journal:  Am J Surg Pathol       Date:  1991-01       Impact factor: 6.394

7.  Mutations of the VHL tumour suppressor gene in renal carcinoma.

Authors:  J R Gnarra; K Tory; Y Weng; L Schmidt; M H Wei; H Li; F Latif; S Liu; F Chen; F M Duh
Journal:  Nat Genet       Date:  1994-05       Impact factor: 38.330

8.  Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys.

Authors:  Christian Rosenberger; Stefano Mandriota; Jan Steffen Jürgensen; Michael S Wiesener; Jan H Hörstrup; Ulrich Frei; Peter J Ratcliffe; Patrick H Maxwell; Sebastian Bachmann; Kai-Uwe Eckardt
Journal:  J Am Soc Nephrol       Date:  2002-07       Impact factor: 10.121

9.  Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C.

Authors:  A Kibel; O Iliopoulos; J A DeCaprio; W G Kaelin
Journal:  Science       Date:  1995-09-08       Impact factor: 47.728

10.  Case report: multiple hepatic and pulmonary haemangioblastomas--a new manifestation of von Hippel-Lindau disease.

Authors:  F P McGrath; R G Gibney; D C Morris; D A Owen; S R Erb
Journal:  Clin Radiol       Date:  1992-01       Impact factor: 2.350

View more
  41 in total

1.  MEK2 Negatively Regulates Lipopolysaccharide-Mediated IL-1β Production through HIF-1α Expression.

Authors:  Harvinder Talwar; Mohamad Bouhamdan; Christian Bauerfeld; Jaya Talreja; Rifdat Aoidi; Nicolas Houde; Jean Charron; Lobelia Samavati
Journal:  J Immunol       Date:  2019-02-01       Impact factor: 5.422

Review 2.  Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma.

Authors:  Bryden Considine; Michael E Hurwitz
Journal:  Curr Oncol Rep       Date:  2019-03-08       Impact factor: 5.075

3.  Low tumor glutathione level as a sensitivity marker for glutamate-cysteine ligase inhibitors.

Authors:  Satoru Nishizawa; Hideo Araki; Yoshinori Ishikawa; Satoshi Kitazawa; Akito Hata; Tomoyoshi Soga; Takahito Hara
Journal:  Oncol Lett       Date:  2018-04-10       Impact factor: 2.967

4.  Identification of Cys255 in HIF-1α as a novel site for development of covalent inhibitors of HIF-1α/ARNT PasB domain protein-protein interaction.

Authors:  Rosa Cardoso; Robert Love; Carol L Nilsson; Simon Bergqvist; Dawn Nowlin; Jiangli Yan; Kevin K-C Liu; Jing Zhu; Ping Chen; Ya-Li Deng; H Jane Dyson; Michael J Greig; Alexei Brooun
Journal:  Protein Sci       Date:  2012-11-09       Impact factor: 6.725

5.  Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites.

Authors:  Javier A Menendez; Tomás Alarcón; Jorge Joven
Journal:  Cell Cycle       Date:  2014-02-03       Impact factor: 4.534

6.  Nek1 phosphorylates Von Hippel-Lindau tumor suppressor to promote its proteasomal degradation and ciliary destabilization.

Authors:  Mallikarjun Patil; Navjotsingh Pabla; Shuang Huang; Zheng Dong
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

7.  Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome.

Authors:  Roland Därr; Joan Nambuba; Jaydira Del Rivero; Ingo Janssen; Maria Merino; Milena Todorovic; Bela Balint; Ivana Jochmanova; Josef T Prchal; Ronald M Lechan; Arthur S Tischler; Vera Popovic; Dragana Miljic; Karen T Adams; F Ryan Prall; Alexander Ling; Meredith R Golomb; Michael Ferguson; Naris Nilubol; Clara C Chen; Emily Chew; David Taïeb; Constantine A Stratakis; Tito Fojo; Chunzhang Yang; Electron Kebebew; Zhengping Zhuang; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2016-09-27       Impact factor: 5.678

8.  Expression of hypoxia-inducible factor 3α in hepatocellular carcinoma and its association with other hypoxia-inducible factors.

Authors:  Ping Liu; Xiefan Fang; Yang Song; Jian-Xin Jiang; Qian-Jin He; Xiang-Jie Liu
Journal:  Exp Ther Med       Date:  2016-03-24       Impact factor: 2.447

9.  Expression and significance of HIF-1α and HIF-2α in pancreatic cancer.

Authors:  Min Wang; Mei-Yuan Chen; Xing-Jun Guo; Jian-Xin Jiang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-12-16

Review 10.  CD8+ T cell metabolism in infection and cancer.

Authors:  Miguel Reina-Campos; Nicole E Scharping; Ananda W Goldrath
Journal:  Nat Rev Immunol       Date:  2021-05-12       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.